Gastroenterology

Top Medical News
Radiation therapy may raise colorectal cancer risk among Hodgkin's lymphoma survivors
14 hours ago
Individuals who received radiation therapy for Hodgkin's lymphoma are at increased risk of colorectal cancer, as reported in a study.
Isolated anti-HBc positivity ups liver-related death risk
16 hours ago
Isolated hepatitis B core antibody (anti-HBc) positivity appears to increase the risk of liver-related and liver cancer mortality, particularly when accompanied by a high fibrosis score, according to a study of Korean adults.
SPOTLIGHT shines on zolbetuximab-chemo potential for gastric/GEJ cancer
Audrey Abella, 19 hours ago
A combination regimen comprising zolbetuximab and mFOLFOX6* chemotherapy (CT) regimen showed potential as first-line treatment for claudin-18.2-positive**/HER2-negative (CLDN18.2+/HER2–) locally advanced unresectable or metastatic gastric or gastroesophageal junction (G/GEJ) adenocarcinoma, according to the primary findings of the phase III SPOTLIGHT trial.
Sleep disturbances tied to day-before, split-dose PEG regimens for colonoscopy
Yesterday
Day-before and split-dose high-volume polyethylene glycol (PEG) regimens for patients scheduled to have a colonoscopy are associated with the greatest sleep disturbance, reports a Canada study.
Dietary therapy a useful treatment option in eosinophilic esophagitis
2 days ago
Diet modification appears to be effective for treating eosinophilic esophagitis (EoE), with an overall histological remission rate of 53.8 percent, according to the results of a meta-analysis.
Prebiotic supplementation beneficial in mild to moderate ulcerative colitis
3 days ago
Oral supplementation with 1-kestose in patients with mild to moderate ulcerative colitis helps modulate the gut microbiome, which in turn contributes to clinical improvement, as reported in a study.
130/80 home BP equivalent to clinic BP for stage 1 hypertension
Stephen Padilla, 3 days ago
The addition of bevacizumab (BVZ) to the standard regimen for the treatment of advanced colorectal cancer (CRC) appears to increase the risk of cardiovascular events, suggest the results of a meta-analysis presented at the recent ASCO Gastrointestinal Cancers Symposium (ASCO GI 2023).
Special Reports
Product Highlight - Ravida
13 Sep 2022
Ravidasvir 200 mg tab
Product Highlight - Salofalk
12 Mar 2021
SALOFALK – Mesalazine 1.5 g PR granules
Relationship between tumour response to systemic therapy and overall survival in unresectable hepatocellular carcinoma
Dr Raghav Sundar, 09 Sep 2019

Overall survival (OS) is currently the primary criteria in assessing the efficacy of a cancer treatment. Dr Raghav Sundar, a consultant medical oncologist at the National University Hospital, Singapore, details the crucial role played by tumour response in evaluating treatment efficacy, with a focus on the multiple kinase inhibitor lenvatinib in the treatment of hepatocellular carcinoma (HCC).  

Conference Reports
SPOTLIGHT shines on zolbetuximab-chemo potential for gastric/GEJ cancer
Audrey Abella, 06 Feb 2023
A combination regimen comprising zolbetuximab and mFOLFOX6* chemotherapy (CT) regimen showed potential as first-line treatment for claudin-18.2-positive**/HER2-negative (CLDN18.2+/HER2–) locally advanced unresectable or metastatic gastric or gastroesophageal junction (G/GEJ) adenocarcinoma, according to the primary findings of the phase III SPOTLIGHT trial.
130/80 home BP equivalent to clinic BP for stage 1 hypertension
Stephen Padilla, 03 Feb 2023
The addition of bevacizumab (BVZ) to the standard regimen for the treatment of advanced colorectal cancer (CRC) appears to increase the risk of cardiovascular events, suggest the results of a meta-analysis presented at the recent ASCO Gastrointestinal Cancers Symposium (ASCO GI 2023).
Palliative RT relieves pain in end-stage liver cancer
Stephen Padilla, 02 Feb 2023
Treatment with single fraction radiation therapy (RT) results in lesser hepatic pain in most patients with end-stage hepatocellular carcinoma (HCC) or liver metastases, according to a study presented at the recent ASCO Gastrointestinal Cancers Symposium (ASCO GI 2023).
Procalcitonin-based algorithm reduces unnecessary antibiotic use in acute pancreatitis
Roshini Claire Anthony, 01 Jan 2023

A procalcitonin-guided algorithm could reduce the unnecessary use of antibiotics in patients with acute pancreatitis, according to results of the PROCAP trial.

Bepirovirsen shows promise in controlling chronic HBV infection
Roshini Claire Anthony, 19 Dec 2022

Weekly bepirovirsen treatment may help reduce HBsAg* and hepatitis B virus (HBV) DNA levels in patients with chronic HBV infection, the phase IIb B-Clear study showed.

ALXN1840 generates rapid, sustained copper mobilization in Wilson disease
Audrey Abella, 15 Dec 2022
In individuals with Wilson disease (WD), a rare disease of copper metabolism, ALXN1840 led to significantly greater copper mobilization compared with standard of care (SoC), findings from a rater-blinded phase III study have shown.
Maralixibat improves pruritus across all PFIC types
Elaine Soliven, 14 Dec 2022
Treatment with maralixibat significantly reduced the severity of pruritus in children with progressive familial intrahepatic cholestasis (PFIC) in the MARCH-PFIC* study presented at The Liver Meeting 2022.